Sung Bae Kim

Sung Bae Kim

Auto-generated profile, based on publicly available information

Sung Bae Kim

Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2020 in Gut and Liver
Verified
Journal Article
Open access
PDF file
SKSung Bae Kim
Sung Bae Kim
JCJae Hee Cheon
Jae Hee Cheon
JPJae Jun Park
Jae Jun Park
EKEun Soo Kim
Eun Soo Kim
SJSeong Woo Jeon
Seong Woo Jeon
GSGeom Seog Seo
Geom Seog Seo
Sung Bae Kim, Jae Hee Cheon, Jae Jun Park, Eun Soo Kim, Seong Woo Jeon, Sung-Ae Jung, Dong Il Park, Chang Kyun Lee, Jong Pil Im, You Sun Kim, Hyun Soo Kim, Jun Lee, Chang Soo Eun, Jeong Mi Lee, Byung Ik Jang, and Geom Seog Seo. Gut and Liver 2020;14:331-7. https://doi.org/10.5009/gnl19085

7 March 2016 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
SKSung Bae Kim
Sung Bae Kim
ASAhmed Sayeed
Ahmed Sayeed
AVAntonio H Villalon
Antonio H Villalon
ZSZhen Zhou Shen
Zhen Zhou Shen
TYTsz Kok Yau
Tsz Kok Yau
TCTsu-Yi Chao
Tsu-Yi Chao
Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia-Pacific Breast Initiatives I and II Adjuvant therapy;docetaxel;early breast cancer;taxanes; Background: The Asia-Pacific Breast Initiatives (APBI) I and II registries were established to collect safety data for patients with early stage breast cancer receiving adjuvant docetaxel-based regimens in the Asia-Pacific region. Materials and Methods: Data from the two registries were combined to perform a safety analysis. Participants in the registry were women with early stage operable breast cancer with an intermediate or high risk of recurrence. These women received adjuvant chemotherapy that included docetaxel between 2006 and 2011. Adverse events (AEs) were recorded and analyzed. Results: Data were collected from 3,224 patients from 13 countries. The mean dose intensity of docetaxel was 24.1, 22.7, $25.1mg/m^2/week$ among patients receiving docetaxel-based monotherapy, combination therapy and sequential therapy, respectively. Granulocyte colony-stimulating factor (G-CSF) was given with docetaxel to 41.8% of women and 20.6% of women receiving prophylactic antibiotics. Adverse events were reported in 86% of patients (anthracycline-containing regimens vs. non-anthracycline regimens; 87% vs. 80%). The most common adverse events were alopecia, nausea, neutropenia, vomiting, and myalgia. Adverse events NCI CTCAE ${\geq}$Grade 3 were reported in 45.4% of patients. Serious adverse events were reported in 13% of patients, of which 2.5% led to study discontinuation. Forty-six deaths (1.4%) were reported, with no significant difference between regimens. Conclusions: The safety parameters of adjuvant docetaxel therapy used to treat sequential Asian women were comparable to those reported in clinical trials evaluating the role of adjuvant docetaxel. No unusual adverse events linked to Asia-Pacific region patients were observed.

31 August 2015 in Journal of the Korean Society of Hazard Mitigation
Verified
Journal Article
Open access
SKSung Bae Kim
Sung Bae Kim
MKMin Joung Kang
Min Joung Kang
SCSeong Hyun Cho
Seong Hyun Cho
SKSang Seup Kim
Sang Seup Kim